Abstract: The present disclosure provides methods, systems, and media for optimized customer relationship management. A method for identifying subjects for a clinical procedure may comprise (a) retrieving, from a computer database, a first set of subject records, wherein the first set of subject records corresponds to a first set of subjects that are candidates for the clinical procedure; (b) processing the first set of subject records using a trained machine learning algorithm to generate a second set of subject records; and (c) electronically outputting the second set of subject records.

Abstract: The present disclosure generally relates to a system for crime risk forecasting using cyber security and deep learning comprises a data input unit for receiving a pre-stored crime event dataset and real time crime event data input along with geographical details of an area; a classification processing unit for categorizing pre-stored crime event dataset and real time crime event data input according to crime type; a graphical user interface for entering a target geographic area for forecasting upcoming crime risk; a central processing unit for generating a crime risk forecast based on the historical crime incident stored in the pre-stored crime event dataset using a deep leaning technique; and a control unit coupled to a display for displaying a crime risk ranking generated based on the crime risk forecast and one or more crime risk event for the target geographic area.

Abstract: The invention provides methods and compositions involving the compounds N?-(3,5-dimethylbenzoyl)picolinohydrazide; N?-(pyridin-2-yl)picolinohydrazide or pharmaceutically acceptable salts thereof for inhibiting the function of histone demethylases in vivo and in vitro, as well as methods for treating cancer comprising the administration of such compositions.

Abstract: Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.

Abstract: Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.

Abstract: Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.

Abstract: A method at a user equipment in an LTE system includes selecting one of a number of CDMA systems, and signaling indication(s) of the selected CDMA system to a network element. The network element receives indication(s) of CDMA system(s), which correspond to requested action(s) by a UE. The network element routes information corresponding to the requested action(s) to the CDMA system(s). Another network element in the LTE system signals to the UE indications of a mapping of a number of CDMA systems to associated ones of LTE system(s). The other network element receives signaling from the UE including indication(s) of selected CDMA system(s) selected by the UE.

Abstract: A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition.

Abstract: A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition.

Abstract: A method at a user equipment in an LTE system includes selecting one of a number of CDMA systems, and signaling indication(s) of the selected CDMA system to a network element. The network element receives indications) of CDMA system(s), which correspond to requested action(s) by a UE. The network element routes information corresponding to the requested action(s) to the CDMA system(s). Another network element in the LTE system signals to the UE indications of a mapping of a number of CDMA systems to associated ones of LTE system(s). The other network element receives signaling from the UE including indication(s) of selected CDMA system(s) selected by the UE.

Abstract: A method of predicting the outcome of a patient with neuroblastoma that includes obtaining experimental data on gene selections. The gene selection functions to predict the outcome of a patient with neuroblastoma when the expression of that gene selection is compared to the identical selection from a non-neuroblastoma cell or a different type of neuroblastoma cell. The invention also includes a method of targeting at least one product of a gene that includes administration of a therapeutic agent. The invention also includes the use of a gene selection for predicting the outcome of patient with neuroblastoma.

Abstract: A method of diagnosing a disease that includes obtaining experimental data on gene selections. The gene selection functions to characterize a cancer when the expression of that gene selection is compared to the identical selection from a noncancerous cell or a different type of cancer cell. The invention also includes a method of targeting at least one product of a gene that includes administration of a therapeutic agent. The invention also includes the use of a gene selection for diagnosing a cancer.

Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR4 variants, which are linked to increased risk of tumor metastasis. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.

Abstract: A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition.

Abstract: A microarray apparatus is provided which contains at least one chip having source and drain electrodes positioned on an array of carbon nanotube transistors which allows for electronic detection of nucleic acid hybridizations, thereby affording both increased sensitivity and the capability of miniaturization.

Abstract: A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition.

Abstract: A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition.

Abstract: A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition.

Abstract: A method of diagnosing a disease that includes obtaining experimental data on gene selections. The gene selection functions to characterize a cancer when the expression of that gene selection is compared to the identical selection from a noncancerous cell or a different type of cancer cell. The invention also includes a method of targeting at least one product of a gene that includes administration of a therapeutic agent. The invention also includes the use of a gene selection for diagnosing a cancer.

Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR4 variants, which are linked to increased risk of tumor metastasis. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.